Bachem Holding AG (BANB) AI Stock Analysis

• Market Cap: CHF4.76B
• Dividend Yield: 1.43%
• Average Volume (3M): 109.83K
• Price to Earnings (P/E): 30.2
• Beta (1Y): 0.78
• Revenue Growth: 17.34%
• EPS Growth: 18.15%
• Country: CH
• Employees: 2,207
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): 1.32
• Shares Outstanding: 75,000,000
• 10 Day Avg. Volume: 97,857
• 30 Day Avg. Volume: 109,830
• PEG Ratio: 1.27
• Price to Book (P/B): 3.08
• Price to Sales (P/S): 6.46
• P/FCF Ratio: -93.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF83.20
• Price Target Upside: 31.02% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 2.4
• Revenue Forecast (FY): CHF954.60M

• Rating: 62 Neutral
• Price Target: CHF63.00 ▼(-0.79% Downside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is mainly supported by strong underlying financial quality (high profitability and very low leverage), but it is held back by persistently negative free cash flow and weak technical momentum. Valuation appears on the expensive side given the P/E, with only modest support from the dividend yield.

Positive Factors

Very conservative balance sheet / low leverage

Extremely low leverage provides durable financial flexibility: it reduces refinancing and solvency risk, supports multi-year supply commitments and capital projects, and allows management to invest in capacity or weather demand cyclicality without relying on large external funding.

Negative Factors

Persistent negative free cash flow

Sustained negative free cash flow erodes the company's ability to self-fund growth, dividends, or unexpected shocks. Even with positive operating cash in absolute terms, chronic FCF deficits indicate capital intensity or working-capital strain that can force external financing or slower return of capital.

Bachem Holding AG Business Overview & Revenue Model

Company Description

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide activ...

Read more

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide activ...

How the Company Makes Money

Bachem primarily makes money by selling peptide-based pharmaceutical ingredients and by providing contract development and manufacturing services. A major revenue stream is the manufacture and supply of peptide APIs for customers’ marketed drugs (...

Read more

Bachem primarily makes money by selling peptide-based pharmaceutical ingredients and by providing contract development and manufacturing services. A major revenue stream is the manufacture and supply of peptide APIs for customers’ marketed drugs (...

Bachem Holding AG Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	695.07M	605.26M	577.32M	531.74M	503.23M
Gross Profit	199.73M	182.56M	176.96M	171.28M	166.73M
EBITDA	189.88M	178.76M	163.28M	160.54M	156.47M
Net Income	148.79M	120.25M	111.86M	100.68M	114.68M
Balance Sheet
Total Assets	2.11B	1.92B	1.68B	1.38B	1.30B
Cash, Cash Equivalents and Short-Term Investments	30.99M	95.20M	298.53M	268.43M	442.36M
Total Debt	57.39M	290.00K	401.00K	691.00K	20.86M
Total Liabilities	650.41M	531.88M	362.36M	214.21M	177.50M
Stockholders Equity	1.46B	1.39B	1.32B	1.17B	1.12B
Cash Flow
Free Cash Flow	-48.20M	-138.30M	-18.54M	-49.76M	-19.66M
Operating Cash Flow	271.36M	146.32M	249.86M	92.59M	97.16M
Investing Cash Flow	-325.22M	-148.88M	-170.81M	-63.17M	-469.13M
Financing Cash Flow	-9.52M	-61.26M	48.69M	-86.93M	437.58M

Bachem Holding AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 63.50
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Positive. The current price of 63.5 is above the 20-day moving average (MA) of 59.93, below the 50-day MA of 63.56, and above the 200-day MA of 60.34, indicating a neutral trend. The MACD of 0.60 indicates Negative momentum. The RSI at 56.76 is Neutral, neither overbought nor oversold. The STOCH value of 76.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BANB.

Bachem Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
YPSN	70 Outperform	CHF3.78B	7.66	27.15%	0.67%	27.63%	160.67%
BANB	62 Neutral	CHF4.76B	30.18	9.76%	1.43%	17.34%	18.15%
SFZN	62 Neutral	CHF3.31B	19.36	15.79%	0.51%	0.77%	16.70%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
GALE	61 Neutral	CHF4.53B	26.89	―	2.36%	5.84%	8.57%
LONN	56 Neutral	CHF33.97B	19.54	―	0.75%	5.93%	29.83%
PPGN	46 Neutral	CHF881.93M	-43.40	―	―	12.03%	-19.29%

Bachem Holding AG Corporate Events